Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

The Surgical Results of Stage I Lung Cancer

제 1기 폐암의 수술성적

  • 김길동 (연세대학교 의과대학 흉부외과학교실) ;
  • 정경영 (연세대학교 의과대학 흉부외과학교실) ;
  • 홍기표 (연세대학교 의과대학 흉부외과학교실) ;
  • 김대준 (연세대학교 의과대학 흉부외과학교실)
  • Published : 1998.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Surgical resection is the standad therapy for the stage I lung cancer. We analysed the risk facturs of stage I lung cancer patent and tryed to establish more effective and aggressive treatment modality. Materials and methods: A detailed analysis was undertaken to evaluate the surgical results and to define the risk factors associated with the recurrence and the survival time in 146 consecutive patients with stage I lung cancer who were diagnosed, and resected at Yonsei Medical Center from January 1990 to December 1996. Results: There were 115 males and 31 females. Their ages ranged from 27 to 79 years(mean age:58.9$\pm$9.3 years). The histologic types were squamous carcinoma in 72 cases(49.3%) and adenocarcinoma in 45 cases(30.8%). A pulmonary resection and mediastinal lymph node dissection were done in all cases. A lobectomy was performed in 96 cases(65.7%) and a pneumonectomy in 48 cases(32.9%). There were 5 operative mortalities(3.4%) and complications occured in 24 cases(16.5%). The overall 5-year survival was 64.1%, and survival time did not depend on the type of operation or histologic type. Significant predictors of decreased survival were visceral pleural invasion(p=0.0079), T2 lesion(p=0.0462), and tumor size($\geq$5 cm) in adenocarcinoma(p=0.0472). The overall incidence of recurrence was 33.3%(47 cases; local or regional 6.4%, distant 26.9%). Almost all recurrences(44cases) occurred in T2 lesions. The distant organs that failed were the contralateral lung in 13 patients, the brain in 12, the bone in 10, and other organs in 3. Conclusions: even in stage I lung cancer, we suggest that postoperative adjuvant therapy is recommended in patients with poor prognostic factors such as visceral pleural invasion, T2 lesions, and a tumor size($\geq$5 cm) in the adenocarcinoma.

연세대학교 의과대학 신촌세브란스병원 흉부외과에서는 1990년 1월부터 1996년 12월까지 원발성 폐암으로 폐절제술을 시행한 환자중 병리학적 병기가 제 1기인 146명을 대상으로 분석 하였다. 이중 남자는 115명, 여자가 31명이었고 나이는 27세에서 79세까지로 평균 58.9세 이었다. 세포병리학적 분류로 상피세포암이 7 2례(49.3%), 선암이 45례(30.8%)로 대부분 이었고, 수술은 전례에서 폐절제술과 종격동 임파절 박리술을 시행하였으며 폐엽 절제술이 96례(65.7%), 전폐 절제술이 48례(32.9%)이었다. 수술사망은 5례(3.4%), 합병증은 24례(16.5%)에서 발생하였다. 5년 생존율은 64.1% 이었으며 평균 생존기간은 66.5개월이었다. 예후인자별 분석에서 수술범위(p=0.1165), 세포형(p=0.8893)에 따른 생존율의 차이는 없었으며, 장측늑 막의 침윤 여부(p=0.0079), T1과 T2(p=0.0462), 선암에서 종양의 크기(>=5 cm)(p=0.0472)에 따른 생존율은 의미있는 차이를 보였다. 수술후 재발은 47례(33.3%)에서 발생 하였고, 이중 국소재발이 9례, 원격전이가 38례 이었다. 재발된 례중 대부분인 44례(93.7%)가 T2병변에서 재발되었고 3례(6.4%)만이 T1병변에서 재 발 되었다. 원격전이가 일어난 부위로는 반대편 폐가 13례로 가장 많았고 뇌 12례, 골 10례등 이었다. 결 론으로 장측늑막의 침윤, T2 병변, 선암에서 크기가 5 cm 이상인 경우에는 제 1기 폐암이라 할 지라도 수 술후 보조치료를 고려해 볼 수 있으리라 사료되었다.

Keywords

References

  1. CA Cancer J Clin v.46 no.3 Clinical highlights from the National Cancer Data Base Jessup JM;McGinnis LS;Winchester DR(et al.)
  2. Chest v.89 A new international staging system for lung cancer Mountain CF
  3. J Thorac Cardiovasc Surg v.96 Prognosis and survival in resected lung carcinoma based on the new international staging system Naruke T;Goya T;Tsuchiya R(et al.)
  4. Cancer v.70 New aspects in the staging of lung cancer. Prospective validation of the international Union Against Caner TNM classification Bulzebruk H;Bopp R;Dring P(et al.)
  5. Current controversies in thoracic surgery Lobectomy for stage Ⅰlung cancer Martini N;McCaughan BC;McCormack P(et al.);Kittle CF(ed.)
  6. J Thorac Cardiovasc Surg v.109 no.1 Incidence of local recurrence and second primary tumors in resected stage Ⅰ lung cancer Martinin N;Bains MS;Burt ME(et al.)
  7. J Thorac Cardiovasc Surg v.106 no.1 Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage Ⅰ non-small cell lung cancer? Ichinose Y;Hara N;Ohta M(et al.)
  8. Cancer v.76 no.5 Stage 1 nonsmall cell lung cancer Harpole DH Jr;Herndon JE Ⅱ;Young WG Jr;Wolfe WG;Sabiston DC Jr
  9. Ann Thorac Surg v.60 Survival in early stage non-small cell cancer Nesbitt JC;Putnam JB Jr;Walsh GL;Roth JA;Mountain CF
  10. Ann Thorac Surg v.49 Survival after conservative resection for T1NOMO non small cell lung cancer Read RC;Yoder G;Schaeffer RC
  11. Presented at the Lung Cancer Study Group: final analysis meeting LCSG 821- The comparison of limited resection to lobectomy for T1NO non small cell lung cancer Ginsberg RJ(et al.)
  12. J Surg Oncol v.35 Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population Mountain CF;Lukeman JM;Hammer SP
  13. Cancer v.54 Prognostic factors in patients; with resected stage Ⅰ non small cell lung cancer-a report from the Lung Cancer Study Group Gail MH;Eagan RT;Feld R(et al.)
  14. Eur J Cardiothorac Surg v.5 Survival and prognosis following resection of primary non small cell bronchogenic carcinoma Kadri MA;Dussek JE
  15. Surg Gynecol Obstet v.157 Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of lung Shields TW
  16. J Thorac Cardiovasc Surg v.106 Blood vessel invasion by tumor cells predicts recurrence in completely resected T1NOMO non-small cell lung cancer Macchiarini P;Fontanini G;Hardin MJ(et al.)
  17. J Surg Oncol v.46 Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and postrecurrent survival Ichinose Y;Hara N;Ohta M;Motohiro A;Kuda T;Asoh H
  18. Cancer v.69 A flow cytometric study of non small cell lung cancer classified as T1NO Schmidt RA;Rush VW;Piantadosi S
  19. Jpn J Clin Oncol v.21 Proposal regarding some deficiencies in the new international staging system for non small cell lung cancer Watanabe Y;Shimizu J;Oda M(et al.)
  20. Eur J Cardio-thorac Surg v.9 Locan and/or distant recurrences in T1-2/NO-1 non small cell lung cancer Cangemi V;Volpino P;Andrea ND;Puopolo M(et al.)